Idiopathic Short Stature (ISS) Overview

Save information for later
Sign Up

Learn About Idiopathic Short Stature (ISS)

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Idiopathic Short Stature (ISS) Local Doctors?
Elite in Idiopathic Short Stature (ISS)
Elite in Idiopathic Short Stature (ISS)
Giessen, HE, DE 

Werner Blum practices in Giessen, Germany. Mr. Blum is rated as an Elite expert by MediFind in the treatment of Idiopathic Short Stature (ISS). His top areas of expertise are Idiopathic Short Stature (ISS), Short Stature (Growth Disorders), Hypopituitarism, and Growth Hormone Deficiency (GHD).

Elite in Idiopathic Short Stature (ISS)
Elite in Idiopathic Short Stature (ISS)
Tokyo, JP 

Maki Fukami practices in Tokyo, Japan. Fukami is rated as an Elite expert by MediFind in the treatment of Idiopathic Short Stature (ISS). Their top areas of expertise are Intersex, Idiopathic Short Stature (ISS), Short Stature (Growth Disorders), and Russell-Silver Dwarfism.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Idiopathic Short Stature (ISS)
Elite in Idiopathic Short Stature (ISS)
Nanchang, CN 

Xijuan Liu practices in Nanchang, China. Liu is rated as an Elite expert by MediFind in the treatment of Idiopathic Short Stature (ISS). Their top areas of expertise are Idiopathic Short Stature (ISS), Short Stature (Growth Disorders), Osteosarcoma, and Bone Tumor.

What are the latest Idiopathic Short Stature (ISS) Clinical Trials?
A Multicenter, Observational Study to Characterize Growth in Children With Idiopathic Short Stature

Summary: Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Multicenter, Randomized, Open-Label, Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Inpegsomatropin Injection, s.c Once a Week, Compared With Recombinant Human Growth Hormone (rhGH) Injection in Children With Idiopathic Short Stature (ISS).

Summary: This is a multicenter, randomized, open-label, active-controlled Phase III clinical trial to evaluate the efficacy and safety of Inpegsomatropin injection,once a week,compared with recombinant human growth hormone (rhGH) in children with idiopathic short stature (ISS). It plans to enroll 300 children with ISS, who will be randomized , stratified by gender and age, and assigned to either the experi...